MyTACTIC: Afficacy and safety of atezolizumab (atezo) plus chemotherapy (chemo) in patients (pts) with advanced unresectable/metastatic solid tumors with high tumor mutational burden (TMB-H) or high microsatellite instability (MSI-H)/deficient mismatch repair (dMMR)

被引：0
|
作者：
Spigel, David R.
Hussein, Maen A.
Zuniga, Richard
Mahadevan, Daruka
Winn, Robert
Darbonne, Walter C.
Yoo, Bongin
Kim, Young
Whitehead, Zach
Vanderwalde, Ari M.
机构：
[1] Sarah Cannon Res Inst, Dept Thorac Med Oncol, Tennessee Oncol, Nashville, TN USA
[2] Florida Canc Specialists Sarah Cannon Res Inst, Leesburg, FL USA
[3] OneOncol Inc, Precis Med, Nashville, TN USA
[4] New York Canc & Blood Specialists, Port Jefferson Stn, NY USA
[5] Univ Texas Hlth San Antonio MD Anderson Canc Ctr, Div Hematol & Med Oncol, Mays Canc Ctr, San Antonio, TX USA
[6] Virginia Commonwealth Univ, Dept Hlth Behav & Policy, Richmond, VA USA
[7] Genentech Inc, US Med Affairs Oncol, South San Francisco, CA USA
[8] Caris Life Sci, West Canc Ctr & Res Inst, Germantown, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2612
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparative molecular analysis between microsatellite instability-high (MSI-H) tumors with high tumor mutational burden (TMB-H) versus MSI-H tumors with TMB-intermediate/low
    Salem, M. E.
    Puccini, A.
    Grothey, A.
    Xiu, J.
    Goldberg, R.
    Kim, E. S.
    Korn, W. M.
    Lenz, H-J.
    Raghavan, D.
    Marshall, J. L.
    Hall, M. J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [2] Prevalence of high tumor mutational burden (TMB-H) and microsatellite instability-high (MSI-H) status in neuroendocrine neoplasms
    Padda, Sukhmani Kaur
    Aggarwal, Rahul Raj
    Ashok, Arya
    Mauer, Elizabeth
    Shirazi, Maryam
    Bergsland, Emily K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review
    Lorenzi, Maria
    Amonkar, Mayur
    Zhang, Jacky
    Mehta, Shivani
    Liaw, Kai-Li
    [J]. JOURNAL OF ONCOLOGY, 2020, 2020
  • [4] STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS
    Lorenzi, M.
    Amonkar, M.
    Zhang, J.
    Mehta, S.
    Liaw, K.
    [J]. VALUE IN HEALTH, 2018, 21 : S22 - S23
  • [5] A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
    Guo, W.
    Bi, F.
    Dong, J.
    Jin, C.
    Niu, Z.
    Wang, Y.
    Sun, M.
    Wang, T.
    Yu, D.
    He, Y.
    Zhang, R.
    Yin, X.
    Feng, W.
    Zhang, M.
    Li, L.
    Zhang, B.
    Kang, X.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1511 - S1511
  • [6] Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study
    Guo, Weijian
    Bi, Feng
    Dong, Jian
    Jin, Chuan
    Niu, Zuoxing
    Wang, Yusheng
    Sun, Meili
    Wang, Teng
    Yu, Dajun
    He, Yifu
    Zhang, Ruixing
    Yin, Xianli
    Feng, Wenlei
    Zhang, Meijiang
    Zhang, Baihui
    Li, Lingyan
    Kang, Xiaoyan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Xu, Yaling
    Wang, Yidi
    Fei, Cong
    Shen, Lin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [8] SYSTEMATIC AND STRUCTURED REVIEWS OF THE DISEASE BURDEN IN PATIENTS WITH MICROSATELLITE INSTABILITY HIGH (MSI-H) OR MISMATCH REPAIR DEFICIENT (DMMR) COLORECTAL CANCER (CRC)
    Amonkar, M.
    Chase, M.
    Takyar, J.
    Sharma, S.
    [J]. VALUE IN HEALTH, 2021, 24 : S24 - S24
  • [9] FREQUENCY OF AND TESTING PATTERNS FOR MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS IN A US COMMUNITY ONCOLOGY SETTING
    Chase, M.
    Vasudevan, A.
    Amonkar, M.
    Myer, N.
    Wang, T.
    Prabhu, V
    Turzhitsky, V
    Spira, A.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S452 - S452
  • [10] Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Xu, Yaling
    Wang, Yidi
    Fei, Cong
    Shen, Lin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345